Product Description
MediciNova is developing Ibudilast as a treatment for drug addiction, progressive multiple sclerosis, and pain. (Sourced from: https://medicinova.com/clinical-development/core/mn-166/)
Mechanisms of Action: PDE4 Inhibitor,TLR4 Antagonist,LT Antagonist,MIF Inhibitor,NOS Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Korea
Approved Indications: None
Known Adverse Events: None
Company: MediciNova
Company Location: LA JOLLA CA 92037
Company CEO: Yuichi Iwaki
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Amyotrophic Lateral Sclerosis|Neck Pain
Phase 2: Alcoholism|COVID-19|Glioblastoma|Pneumonia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| COMBAT-ALS | P3 |
Recruiting |
Amyotrophic Lateral Sclerosis |
2025-12-01 |
95% |
| RECEDE Myelopathy | P3 |
Unknown status |
Neck Pain |
2025-03-06 |
|
| MN-166-GBM-1201 | P2 |
Active, not recruiting |
Glioblastoma |
2023-12-31 |
|
| R01AA026190 | P2 |
Completed |
Alcoholism |
2023-04-19 |